Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Kiniksa Pharmaceuticals, GmbH”

9 pharma patents match "Kiniksa Pharmaceuticals, GmbH" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 9
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 9 pharmaceutical patents matching "Kiniksa Pharmaceuticals, GmbH" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

9 results for “Kiniksa Pharmaceuticals, GmbH” · 30,257 patents in full index Clear search

  1. US 12234294

    Pharmaceutical composition of a humanized anti-CD40 antibody

    Kiniksa Pharmaceuticals, GmbH · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  2. US 12122837

    Oncostatin M receptor antigen binding proteins

    Kiniksa Pharmaceuticals, GmbH · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  3. US 11141479

    Stable anti-OSMR antibody formulation

    Kiniksa Pharmaceuticals, GmbH · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  4. US 10493149

    Stable anti-OSMR antibody formulation

    Kiniksa Pharmaceuticals, GmbH · Granted Dec 3, 2019 · Expires Nov 28, 2039

    granted
  5. US 10421813

    Oncostatin M receptor antigen binding proteins

    Kiniksa Pharmaceuticals, GmbH · Granted Sep 24, 2019 · Expires Sep 19, 2039

    granted
  6. US 10391170

    Stable anti-OSMR antibody formulation

    Kiniksa Pharmaceuticals, GmbH · Granted Aug 27, 2019 · Expires Aug 22, 2039

    granted
  7. US 9738721

    Oncostatin M receptor antigen binding proteins

    Kiniksa Pharmaceuticals, GmbH · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  8. US 9663571

    Oncostatin M receptor antigen binding proteins

    Kiniksa Pharmaceuticals, GmbH · Granted May 30, 2017 · Expires May 25, 2037

    granted
  9. US 9593163

    Oncostatin M receptor antigen binding proteins

    Kiniksa Pharmaceuticals, GmbH · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted